Literature DB >> 19561860

Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia.

Kwaku Marfo1, Yi Guo.   

Abstract

We conducted a retrospective study to assess pharmacoeconomic outcomes of patients who received a daily dose of micafungin 100 mg or 150 mg to treat candidemia. The once-daily 100-mg dose resulted in clinical and mycological outcomes similar to those achieved with 150 mg daily and succeeded in reducing drug-acquisition costs for treating hospitalized patients with candidemia.

Entities:  

Keywords:  candidemia; micafungin; pharmacoeconomics

Year:  2009        PMID： 19561860      PMCID： PMC2697091     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  10 in total

Review 1.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 2.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

Authors:  Nathan P Wiederhold; Russell E Lewis
Journal:  Expert Opin Investig Drugs       Date:  2003-08       Impact factor: 6.206

3.  The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

Authors:  A M Rentz; M T Halpern; R Bowden
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

4.  A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

Authors:  N T E de Wet; A J Bester; J J Viljoen; F Filho; J M Suleiman; E Ticona; E A Llanos; C Fisco; W Lau; D Buell
Journal:  Aliment Pharmacol Ther       Date:  2005-04-01       Impact factor: 8.171

5.  International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Authors:  L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

6.  Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

Authors:  W E Trick; S K Fridkin; J R Edwards; R A Hajjeh; R P Gaynes
Journal:  Clin Infect Dis       Date:  2002-08-02       Impact factor: 9.079

7.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

8.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

9.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Authors:  Peter G Pappas; Coleman M F Rotstein; Robert F Betts; Marcio Nucci; Deepak Talwar; Jan J De Waele; Jose A Vazquez; Bertrand F Dupont; David L Horn; Luis Ostrosky-Zeichner; Annette C Reboli; Byungse Suh; Raghunadharao Digumarti; Chunzhang Wu; Laura L Kovanda; Leah J Arnold; Donald N Buell
Journal:  Clin Infect Dis       Date:  2007-08-29       Impact factor: 9.079

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079
  10 in total
  1 in total

1.  "De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany.

Authors:  Anke van Engen; Montserrat Casamayor; Soyoung Kim; Maureen Watt; Isaac Odeyemi
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.